Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
The Journal of Biological Chemistry
|
March 14, 1997
Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry
J Fantini, D Hammache, O Delézay, et al.
Virology
|
November 1, 1994
Interferon-gamma decreases cell surface expression of galactosyl ceramide, the receptor for HIV-1 GP120 on human colonic epithelial cells
N Yahi, S L Spitalnik, K A Stefano, et al.
The Journal of Biological Chemistry
|
May 9, 1998
Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3
D Hammache, G Piéroni, N Yahi, et al.
Research in Virology
|
September 1, 1992
Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication
S Venaud, N Yahi, J L Fehrentz, et al.
AIDS (London, England)
|
November 1, 1993
High viral burden in lymph nodes during early stages of HIV-1 infection
A Lafeuillade, C Tamalet, P Pellegrino, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 23, 1995
SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms
N Yahi, J Fantini, S Baghdiguian, et al.
Virology
|
May 4, 2000
Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations
C Tamalet, N Yahi, C Tourrès, et al.
Journal of Virology
|
September 1, 1994
Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages
N Yahi, J Fantini, K Mabrouk, et al.
Journal of Clinical Microbiology
|
November 24, 1999
Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences
N Yahi, C Tamalet, C Tourrès, et al.
Journal of Medical Virology
|
May 8, 2000
Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection
C Tamalet, C Pasquier, N Yahi, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
The Journal of Biological Chemistry
|
March 14, 1997
Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry
J Fantini, D Hammache, O Delézay, et al.
Virology
|
November 1, 1994
Interferon-gamma decreases cell surface expression of galactosyl ceramide, the receptor for HIV-1 GP120 on human colonic epithelial cells
N Yahi, S L Spitalnik, K A Stefano, et al.
The Journal of Biological Chemistry
|
May 9, 1998
Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3
D Hammache, G Piéroni, N Yahi, et al.
Research in Virology
|
September 1, 1992
Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication
S Venaud, N Yahi, J L Fehrentz, et al.
AIDS (London, England)
|
November 1, 1993
High viral burden in lymph nodes during early stages of HIV-1 infection
A Lafeuillade, C Tamalet, P Pellegrino, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
May 23, 1995
SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms
N Yahi, J Fantini, S Baghdiguian, et al.
Virology
|
May 4, 2000
Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations
C Tamalet, N Yahi, C Tourrès, et al.
Journal of Virology
|
September 1, 1994
Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages
N Yahi, J Fantini, K Mabrouk, et al.
Journal of Clinical Microbiology
|
November 24, 1999
Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences
N Yahi, C Tamalet, C Tourrès, et al.
Journal of Medical Virology
|
May 8, 2000
Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection
C Tamalet, C Pasquier, N Yahi, et al.
Page
of 6